- Loss of PI3K blocks cell-cycle progression in a Drosophila tumor model
[作者：Willecke, M; Toggweiler, J; Basler, K,期刊：Oncogene, 页码：4067-4074 , 文章类型： Article，,卷期：2011年30-39]
- Tumorigenesis is a complex process, which requires alterations in several tumor suppressor or oncogenes. Here, we use a Drosophila tumor model to identify genes, which are specifically required for tumor growth. We found...
- Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells
[作者：Xing, F; Okuda, H; Watabe, M; Kobayashi, A; Pai, SK; Liu, W; Pandey, PR; Fukuda, K; Hirota, S; Sugai, T; Wakabayshi, G; Koeda, K; Kashiwaba, M; Suzuki, K; Chiba, T; Endo, M; Mo, YY; Watabe, K,期刊：Oncogene, 页码：4075-4086 , 文章类型： Article，,卷期：2011年30-39]
- Notch signaling is often and aberrantly activated by hypoxia during tumor progression; however, the exact pathological role of hypoxia-induced Notch signaling in tumor metastasis is as yet poorly understood. In this stud...
- beta 1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells
[作者：Morello, V; Cabodi, S; Sigismund, S; Camacho-Leal, MP; Repetto, D; Volante, M; Papotti, M; Turco, E; Defilippi, P,期刊：Oncogene, 页码：4087-4096 , 文章类型： Article，,卷期：2011年30-39]
- Lung cancer is the leading cause of cancer death worldwide. The epidermal growth factor receptor (EGFR) represents the main target for non-small cell lung cancer (NSCLC) therapy, as its overexpression or constitutive act...
- Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification
[作者：Tanizaki, J; Okamoto, I; Fumita, S; Okamoto, W; Nishio, K; Nakagawa, K,期刊：Oncogene, 页码：4097-4106 , 文章类型： Article，,卷期：2011年30-39]
- Lapatinib, a dual tyrosine kinase inhibitor of the epidermal growth factor receptor and human epidermal growth factor receptor 2 (HER2), is clinically active in patients with breast cancer positive for HER2 amplification...
- C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer
[作者：Shi, Y; Chen, J; Li, Z; Zhang, Z; Yu, H; Sun, K; Wang, X; Song, X; Wang, Y; Zhen, Y; Yang, T; Lou, K; Zhang, Y; Zhang, G; Hu, Y; Ji, J; Hui, R,期刊：Oncogene, 页码：4107-4117 , 文章类型： Article，,卷期：2011年30-39]
- In an earlier study we showed that C10ORF97 (chromosome-10, open reading frame-97) was expressed in almost all of the tissues and cell lines tested, and that it inhibited the growth of seven tumor cell lines, including t...
- MEK-ERK pathway regulates EZH2 overexpression in association with aggressive breast cancer subtypes
[作者：Fujii, S; Tokita, K; Wada, N; Ito, K; Yamauchi, C; Ito, Y; Ochiai, A,期刊：Oncogene, 页码：4118-4128 , 文章类型： Article，,卷期：2011年30-39]
- EZH2 overexpression occurs in various malignancies and is associated with a poor outcome. We have so far demonstrated that EZH2 downregulates the important genes such as E-cadherin and RUNX3 by increasing histone H3K27 t...
- Farnesoid X receptor inhibits tamoxifen-resistant MCF-7 breast cancer cell growth through downregulation of HER2 expression
[作者：Giordano, C; Catalano, S; Panza, S; Vizza, D; Barone, I; Bonofiglio, D; Gelsomino, L; Rizza, P; Fuqua, SAW; Ando, S,期刊：Oncogene, 页码：4129-4140 , 文章类型： Article，,卷期：2011年30-39]
- Tamoxifen (Tam) treatment is a first-line endocrine therapy for estrogen receptor-alpha-positive breast cancer patients. Unfortunately, resistance frequently occurs and is often related with overexpression of the membran...
|